



29 May 2026

Sydney, Australia

Nyrada Receives A\$2.455M R&D Tax Incentive Rebate

Nyrada Inc (ASX:NYP), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces it has received a AU\$2,454,848 cash rebate from the Australian Federal Government's Research & Development (R&D) tax incentive program.

The R&D rebate relates to expenditures incurred on eligible activities conducted during the 2025 financial year in respect of Nyrada's development of Xolatryp®.

About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca²⁺ entry related to multiple disease pathologies.

[A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed](#) and a [Phase IIa clinical trial](#) has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing myocardial ischemia reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI.

Program Links:

- PROTECT-MI website - <https://www.protect-mi.com>
- Corporate presentation/about MI - <https://bit.ly/4dDWNCz>
- Phase IIa factsheet - <https://bit.ly/4bcDIKj>
- Phase I results - <https://bit.ly/3Nt0GzH>
- GLP study results - <https://bit.ly/4d8VYkX>
- Preclinical anti-tumour study - <https://bit.ly/49rWOa0>
- Preclinical cardioprotection study 1a - <https://bit.ly/4sigwMZ>
- Preclinical cardioprotection study 1b - <https://bit.ly/4rmOsXn>
- Preclinical cardioprotection study 2 - <https://bit.ly/40jHpUg>
- Preclinical traumatic brain injury study - <https://bit.ly/40fhrRT>
- Preclinical stroke study - <https://bit.ly/4sygHmH>

-ENDS-

For personal use only



About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp[®], has shown efficacy in preclinical cardioprotection and neuroprotection models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing myocardial ischemia reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by James Bonnar, Managing Director and CEO, on behalf of the Board.

Investor & Media:

Dimitri Burshtein

T: 0491 789 391

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only